100% tevredenheidsgarantie Direct beschikbaar na betaling Zowel online als in PDF Je zit nergens aan vast
logo-home
NR 602 / NR602 MIDTERM EXAM 2022 – 100% CORRECT AND VERIFIED €14,74   In winkelwagen

Tentamen (uitwerkingen)

NR 602 / NR602 MIDTERM EXAM 2022 – 100% CORRECT AND VERIFIED

 0 keer bekeken  0 aankoop
  • Vak
  • Instelling

Chalazion Chalazion is a chronic sterile inflammation of the eyelid resulting from a lipogranuloma of the meibomian glands that line the posterior margins of the eyelids (see Fig. 29-7). It is deeper in the eyelid tissue than a hordeolum and may result from an internal hordeolum or retaine...

[Meer zien]

Voorbeeld 4 van de 60  pagina's

  • 29 juli 2022
  • 60
  • 2021/2022
  • Tentamen (uitwerkingen)
  • Vragen en antwoorden
avatar-seller
NR 602 / NR602 MIDTERM EXAM 2022 – 100% CORRECT AND VERIFIED



Chalazion
Chalazion is a chronic sterile inflammation of the eyelid resulting from a lipogranuloma of the meibomian
glands that line the posterior margins of the eyelids (see Fig. 29-7). It is deeper in the eyelid tissue than a
hordeolum and may result from an internal hordeolum or retained lipid granular secretions.

Clinical Findings
Initially, mild erythema and slight swelling of the involved eyelid are seen. After a few days the inflammation resolves, and a slow growing,
round, nonpigmented, painless (key finding) mass remains. It may persist for a long time and is a commonly acquired lid lesion seen in
children (see Fig. 29-7).
727

Management
• Acute lesions are treated with hot compresses.
• Refer to an ophthalmologist for surgical incision or topical intralesional corticosteroid injections if the condition is unresolved or if the
lesion causes cosmetic concerns. A chalazion can distort vision by causing astigmatism as a result of pressure on the orbit.

Complications
Recurrence is common. Fragile, vascular granulation tissue called pyogenic granuloma that enlarges and bleeds rapidly can occur if a
chalazion breaks through the conjunctival surface.


Blepharitis
Blepharitis is an acute or chronic inflammation of the eyelash follicles or meibomian sebaceous glands of the eyelids (or both). It is usually
bilateral. There may be a history of contact lens wear or physical contact with another symptomatic person. It is commonly caused by
contaminated makeup or contact lens solution. Poor hygiene, tear deficiency, rosacea, and seborrheic dermatitis of the scalp and face are also
possible etiologic factors. The ulcerative form of blepharitis is usually caused by S. aureus. Nonulcerative blepharitis is occasionally seen in
children with psoriasis, seborrhea, eczema, allergies, lice infestation, or in children with trisomy 21.

Clinical Findings
• Swelling and erythema of the eyelid margins and palpebral conjunctiva
726
• Flaky, scaly debris over eyelid margins on awakening; presence of lice
• Gritty, burning feeling in eyes
• Mild bulbar conjunctival injection
• Ulcerative form: Hard scales at the base of the lashes (if the crust is removed, ulceration is seen at the hair follicles, the lashes fall out, and
an associated conjunctivitis is present)

Differential Diagnosis
Pediculosis of the eyelashes.

Management
Explain to the patient that this may be chronic or relapsing. Instructions for the patient include:
• Scrub the eyelashes and eyelids with a cotton-tipped applicator containing a weak (50%) solution of no-tears shampoo to maintain proper
hygiene and debride the scales.
• Use warm compresses for 5 to 10 minutes at a time two to four times a day and wipe away lid debris.
• At times antistaphylococcal antibiotic (e.g., erythromycin 0.5% ophthalmic ointment) is used until symptoms subside and for at least 1 week
thereafter. Ointment is preferable to eye drops because of increased duration of contact with the ocular tissue. Azithromycin 1% ophthalmic
solution for 4 weeks may also be used (Shtein, 2014).
• Treat associated seborrhea, psoriasis, eczema, or allergies as indicated.
• Remove contact lenses and wear eyeglasses for the duration of the treatment period. Sterilize or clean lenses before reinserting.
• Purchase new eye makeup; minimize use of mascara and eyeliner.
• Use artificial tears for patients with inadequate tear pools.
Chronic staphylococcal blepharitis and meibomian keratoconjunctivitis respond to oral erythromycin. Doxycycline, tetracycline, or
minocycline can be used chronically in children older than 8 years old.

,Acute Otitis Media
AOM is an acute infection of the middle ear (Fig. 30-4). The AAP Clinical Practice Guideline requires the
presence of the following three components to diagnose AOM (Lieberthal et al, 2013):
• Recent, abrupt onset of signs and symptoms of middle ear inflammation and effusion (ear pain, irritability,
otorrhea, and/or fever)
• MEE as confirmed by bulging TM, limited or absent mobility by pneumatic otoscopy, air-fluid level behind
TM, and/or otorrhea
• Signs and symptoms of middle ear inflammation as confirmed by distinct erythema of the TM or onset of ear
pain (holding, tugging, rubbing of the ear in a nonverbal manner)
Characteristics of different types of AOM are defined in Table 30-4. AOM often follows eustachian tube dys-
function (ETD). Common causes of ETD include upper respiratory infections, allergies, and ETS. ETD leads
to 746functional eustachian tube obstruction and inflammation that decreases the protective ciliary action in
the eustachian tube. When the eustachian tube is obstructed, negative pressure develops as air is absorbed in
the middle ear (see Fig. 30-4). The negative pressure pulls fluid from the mucosal lining and causes an
accumulation of sterile fluid. Bacteria pulled in from the eustachian tube lead to the accumulation of purulent
fluid. Young children have shorter, more horizontal and more flaccid eustachian tubes that are easily disrupted
by viruses, which predisposes them to AOM. Respiratory syncytial virus and influenza are two of the viruses
most responsible for the increase in the incidence of AOM seen from January to April. Other risk factors
associated with AOM are listed in Boxes 30-1 and 30-2.
S. pneumoniae, nontypeable Haemophilus influenzae, Moraxella catarrhalis, and S. pyogenes (group A
streptococci) are the most common infecting organisms in AOM (Conover, 2013). S. pneumoniaecontinues to
be the most common bacteria responsible for AOM. The strains of S. pneumoniae in the heptavalent
pneumococcal conjugate vaccine (PCV7) have virtually disappeared from the middle ear fluid of children with
AOM (Lieberthal et al, 2013). With the introduction of the 13-valent S. pneumoniae vaccine, the bacteriology of
the middle ear is likely to continue to evolve. Bullous myringitis is almost always caused by S. pneumonia.
Nontypeable H. influenza remains a common cause of AOM. It is the most common cause of bilateral otitis
media, severe inflammation of the TM, and otitis-conjunctivitis syndrome. M. catarrhalis obtained from the
nasopharynx has become increasingly more beta-lactamase positive, but the high rate of clinical resolution in
children with AOM from M. catarrhalis makes amoxicillin a good choice for initial therapy (Lieberthal et al,
2013). M. catarrhalis rarely causes invasive disease. S. pyogenes is responsible for AOM in older children, is
responsible for more TM ruptures, and is more likely to cause mastoiditis.
Although a virus is usually the initial causative factor in AOM, strict diagnostic criteria, careful specimen
handling, and sensitive microbiologic techniques have shown that the majority of AOM is caused by bacteria or
bacteria and virus together (Lieberthal et al, 2013).

Clinical Findings

History
Rapid onset of signs and symptoms:
• Ear pain with possible ear pulling in the infant; may interfere with activity and/or sleep
• Irritability in an infant or toddler
• Otorrhea
• Fever
Other key factors or symptoms:
• Prematurity
• Craniofacial anomalies or congenital syndromes associated with craniofacial anomalies
• Exposure to risk factors
• Disrupted sleep or inability to sleep
• Lethargy, dizziness, tinnitus, and unsteady gait
• Diarrhea and vomiting
• Sudden hearing loss
• Stuffy nose, rhinorrhea, and sneezing
• Rare facial palsy and ataxia

Physical Examination
• Presence of MEE, confirmed by pneumatic otoscopy, tympanometry, or acoustic reflectometry, as evidenced by:
• Bulging TM (see Fig. 30-4)
• Decreased translucency of TM

, • Absent or decreased mobility of the TM
• Air-fluid level behind the TM
• Otorrhea
747
• Signs and symptoms of middle ear inflammation indicated by either:
• Erythema of the TM (Amber is usually seen in otitis media with effusion [OME]; white or yellow may be seen in either AOM or OME
[Shaikh et al, 2010].)
or
• Distinct otalgia that interferes with normal activity or sleep
• In addition, the following TM findings may be present:
• Increased vascularity with obscured or absent landmarks (see Fig. 30-4).
• Red, yellow, or purple TM (Redness alone should not be used to diagnose AOM, especially in a crying child.)
• Thin-walled, sagging bullae filled with straw-colored fluid seen with bullous myringitis

Diagnostic Studies
Pneumatic otoscopy is the simplest and most efficient way to diagnose AOM. Tympanometry reflects effusion (type B pattern).
Tympanocentesis to identify the infecting organism is helpful in the treatment of infants younger than 2 months old. In older infants and
children, tympanocentesis is rarely done and is useful only if the patient is toxic or immunocompromised or in the presence of resistant
infection or acute pain from bullous myringitis. If a tympanocentesis is warranted, refer the patient to an otolaryngologist for this procedure.

Differential Diagnosis
OME, mastoiditis, dental abscess, sinusitis, lymphadenitis, parotitis, peritonsillar abscess, trauma, ETD, impacted teeth, temporomandibular
joint dysfunction, and immune deficiency are differential diagnoses. Any infant 2 months old or younger with AOM should be evaluated for
fever without focus and not just treated for an ear infection.

Management
Many changes have been made in the treatment of AOM because of the increasing rate of antibiotic-resistant bacteria related to the
injudicious use of antibiotics. Ample evidence has been presented that symptom management may be all that is required in children with
MEE without other symptoms of AOM (Lieberthal et al, 2013). Treatment guidelines are decided based on the child's age, illness severity,
and the certainty of diagnosis. Table 30-5 shows the recommendation for the diagnosis and subsequent treatment of AOM.
1. Pain management is the first principle of treatment.
• Weight-appropriate doses of ibuprofen or acetaminophen should be encouraged to decrease discomfort and fever.
• Topical analgesics, such as benzocaine or antipyrine/benzocaine otic preparations, can be added to systemic pain management if the
TM is known to be intact. Topical analgesics should not be used alone.
• Distraction, oil application, or external use of heat or cold may be of some use.
2. Antibiotics are also effective. (Table 30-6 lists dosage recommendations.)
• Amoxicillin remains the first-line antibiotic for AOM if there has not been a previous treated AOM in the previous 30 days, there is
no conjunctivitis, and no penicillin allergy (Lieberthal et al, 2013). Beta-lactam coverage (amoxicillin/clavulanate, third-
generation cephalosporin) is recommended when the child has been treated with amoxicillin in the previous 30 days, there is an
allergy to penicillin, and the child has concurrent conjunctivitis or has recurrent otitis that has not responded to amoxicillin. If
there is a documented hypersensitivity reaction to amoxicillin, the following antibiotics are acceptable, follow the non-type 1
hypersensitivity and type 1 hypersensitivity recommendations in Table 30-6:
• Ceftriaxone may be effective for the vomiting child, the child unable to tolerate oral medications, or the child who has failed
amoxicillin/clavulanate.
748
• Clindamycin may be considered for ceftriaxone failure but should only be used if susceptibilities are known.
• Prophylactic antibiotics for chronic or recurrent AOM are not recommended.
3. Observation or “watchful waiting” for 48 to 72 hours (see Table 30-5) allows the patient to improve without antibiotic treatment. Pain
relief should be provided, and a means of follow-up must be in place. Options for follow-up include:
• Parent-initiated visit or phone call for worsening or no improvement
• Scheduled follow-up appointment
• Routine follow-up phone call
• Given a prescription to be started if the child's symptoms do not improve or if they worsen in 48 to 72 hours (Table 30-7)
• Communication with the parent, reevaluation, and the ability to obtain medication must be in place.
4. Recommendations for follow-up include:
• After 48 to 72 hours if a child has not showed improvement in ear symptomatology, the child should be seen to confirm or exclude
the presence of AOM. If the initial management option was an antibacterial agent, the agent should be changed.

Prevention and Education
The following interventions, shown to be helpful in preventing AOM, should be encouraged:
• Exclusive breastfeeding until at least 6 months of age seems to be protective against AOM

, • Avoid bottle propping, feeding infants lying down, and passive smoke exposure
• Avoid the use of pacifiers: Although the relationship cannot be fully explained, multiple studies have shown
that pacifier use increases the incidence of AOM (Lieberthal et al, 2013).
• Pneumococcal vaccine; specifically PCV13, which contains subtype 19A
• Annual influenza vaccine may help prevent otitis media
750
• Xylitol liquid or chewing gum as tolerated
• Choose licensed day care facilities with fewer children
• Educate regarding the problem of drug-resistant bacteria and the need to avoid the use of antibiotics unless
absolutely necessary; if antibiotics are used, the child needs to complete the entire course of the prescription
and follow up if symptoms do not resolve


Conjunctivitis
An estimated 6 million cases of bacterial conjunctivitis occur in the United States annually, at an estimated
cost of $377 million to $857 million (Azari and Barney, 2013). Conjunctivitis is an inflammation of the palpebral
and occasionally the bulbar conjunctiva (Fig. 29-5). It is the most frequently seen ocular disorder in pediatric
practice. In pediatric patients, bacteria are the most common cause of infection (50% to 75%) most commonly
from December to April. Pathogens include H. influenzae, Streptococcus pneumoniae, and Moraxella species
with both gram-negative and gram-positive organisms implicated (Azari and Barney, 2013).
Conjunctivitis also occurs as a viral or fungal infection or as a response to allergens or chemical irritants.
Bacterial conjunctivitis is often unilateral, whereas viral conjunctivitis is most often bilateral. Unilateral
disease can also suggest a toxic, chemical, mechanical, or lacrimal cause. Blockage of the tear drainage system
(e.g., from meibomianitis or blepharitis), injury, foreign body, abrasion or ulcers, keratitis, iritis, herpes simplex
virus (HSV), and infantile glaucoma are other known causes. Patient age is a major indicator of etiology ( Table
29-6).
Types of Conjunctivitis


Type Incidence/Etiology Clinical Findings Diagnosis Management*

Saline irrigation to eyes
until exudate gone;
Ophthalmia Neonates: Chlamydia trachomatis, Erythema, Culture (ELISA, PCR), follow with
neonatorum Staphylococcus aureus, Neisseria chemosis, Gram stain, R/O N. erythromycin ointment
gonorrhoeae, HSV (silver nitrate purulent gonorrhoeae,chlamydia For N.
reaction occurs in 10% of neonates) exudate gonorrhoeae:ceftriaxone
with N. or IM or IV
gonorrhoeae; For chlamydia:
clear to erythromycin or possibly
mucoid azithromycin PO
exudate with For HSV: antivirals IV or
chlamydia PO



Neonates: Erythromycin
0.5% ophthalmic
Bacterial In neonates 5 to 14 days old, preschoolers, Erythema, Cultures (required in ointment
conjunctivitis and sexually active teens: Haemophilus chemosis, neonate); Gram stain ≥1 year old: Fourth-
influenzae(nontypeable), Streptococcus itching, (optional); chocolate generation
pneumoniae, S. aureus, N. burning, agar (for N. fluoroquinolone
gonorrhoeae mucopurulent gonorrhoeae) R/O For concurrent AOM: Treat
exudate, pharyngitis, N. accordingly for AOM
matter in gonorrhoeae, AOM, Warm soaks to eyes three
eyelashes; ↑ URI, seborrhea times a day until clear
in winter No sharing towels, pillows
No school until treatment
begins

Depends on prior
treatment, laboratory
Chronic bacterial School-age children and teens: Bacteria, Same as above; Cultures, Gram stain; R/O results, and differential
conjunctivitis viruses, C. trachomatis foreign body dacryostenosis, diagnoses
(unresponsive sensation blepharitis, corneal Review compliance and
conjunctivitis ulcers, trachoma prior drug choices of
previously conjunctivitis treatment

Voordelen van het kopen van samenvattingen bij Stuvia op een rij:

√  	Verzekerd van kwaliteit door reviews

√ Verzekerd van kwaliteit door reviews

Stuvia-klanten hebben meer dan 700.000 samenvattingen beoordeeld. Zo weet je zeker dat je de beste documenten koopt!

Snel en makkelijk kopen

Snel en makkelijk kopen

Je betaalt supersnel en eenmalig met iDeal, Bancontact of creditcard voor de samenvatting. Zonder lidmaatschap.

Focus op de essentie

Focus op de essentie

Samenvattingen worden geschreven voor en door anderen. Daarom zijn de samenvattingen altijd betrouwbaar en actueel. Zo kom je snel tot de kern!

Veelgestelde vragen

Wat krijg ik als ik dit document koop?

Je krijgt een PDF, die direct beschikbaar is na je aankoop. Het gekochte document is altijd, overal en oneindig toegankelijk via je profiel.

Tevredenheidsgarantie: hoe werkt dat?

Onze tevredenheidsgarantie zorgt ervoor dat je altijd een studiedocument vindt dat goed bij je past. Je vult een formulier in en onze klantenservice regelt de rest.

Van wie koop ik deze samenvatting?

Stuvia is een marktplaats, je koop dit document dus niet van ons, maar van verkoper Classroom. Stuvia faciliteert de betaling aan de verkoper.

Zit ik meteen vast aan een abonnement?

Nee, je koopt alleen deze samenvatting voor €14,74. Je zit daarna nergens aan vast.

Is Stuvia te vertrouwen?

4,6 sterren op Google & Trustpilot (+1000 reviews)

Afgelopen 30 dagen zijn er 73314 samenvattingen verkocht

Opgericht in 2010, al 14 jaar dé plek om samenvattingen te kopen

Start met verkopen
€14,74
  • (0)
  Kopen